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Data qualitya b s t r a c t
The Global Polio Eradication Initiative is closer than ever to achieving a polio-free world. Immunization
activities must still be carried out in non-endemic countries to maintain population immunity at levels
which will stop poliovirus from spreading if it is re-introduced from still-infected areas. In areas where
there is no active transmission of poliovirus, programs must rely on surrogate indicators of population
immunity to determine the appropriate immunization activities, typically caregiver-reported vaccination
history obtained from non-polio acute flaccid paralysis patients identified through polio surveillance. We
used regression models to examine the relationship between polio vaccination campaigns and caregiver-
reported polio vaccination history. We find that in many countries, vaccination campaigns have a surpris-
ingly weak impact on these commonly used indicators. We conclude that alternative criteria and data,
such as routine immunization indicators from vaccination records or household surveys, should be con-
sidered for planning polio vaccination campaigns, and that validation of such surrogate indicators is nec-
essary if they are to be used as the basis for program planning and risk assessment. We recommend that
the GPEI and similar organizations consider or continue devoting additional resources to rigorously study
population immunity and campaign effectiveness in at-risk countries.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Since the Global Polio Eradication Initiative (GPEI) began in
1988, the estimated number of cases of poliomyelitis has dropped
by more than 99% [1]. As a result, the number of countries with cir-
culation of wild poliovirus has decreased from over 120 to 3:
Afghanistan, Pakistan, and Nigeria, with wild poliovirus discovered
in Nigeria in August 2016 after a long period of silent circulation
[2]. This dramatic progress has often been interrupted by re-
importation of wild poliovirus into non-endemic countries. Since
2001 there have been wild polio outbreaks from re-introduction
of virus into 41 previously polio-free countries [3], in addition to
outbreaks of circulating vaccine-derived poliovirus in 22 countries
[4]. Such outbreaks highlight the need to maintain high levels of
population immunity globally as long as live poliovirus exists.
The GPEI relies on Supplementary Immunization Activities
(SIAs) to improve areas with low population immunity. These SIAs,
which provide polio vaccine through fixed posts and house-to-
house vaccination campaigns, account for approximately 40% of
the GPEI’s estimated 2013–2018 budget [5]. In 2013, SIAs reached
over 250 million children in over 43 countries at a cost ofapproximately $607 million USD [5]. The frequency and geographic
scope of SIAs varies widely depending on the perceived outbreak
risk and perceived impact of SIAs on population immunity, from
zero SIAs in areas with high routine immunization coverage, to
over 9 SIAs per-year in polio-endemic countries [5]. Given their
financial and epidemiological importance, judicious allocation of
SIAs is a central task of the GPEI.
1.1. Assessing population immunity and polio outbreak risk
When exposure to wild poliovirus was widespread, the occur-
rence of polio cases identified populations with low immunity
and in turn guided the GPEI in the number and geographic scope
of SIAs [6]. However, in the absence of poliovirus detection, the
GPEI must rely on surrogates of polio immunity and perceived risk
of exposure to wild poliovirus to guide vaccination efforts.
The number of SIAs required to prevent transmission of polio-
virus varies widely, depending on routine immunization levels,
vaccination campaign coverage, vaccine efficacy, and local charac-
teristics of the population that influence the transmissibility of
poliovirus, such as population density and sanitation [7]. For an
individual, the number of polio vaccine doses required for protec-
tion from polio varies with vaccine type, vaccine schedule, and
public health factors including sanitation and prevalence of enteric
pathogens [8]. For Type 1 poliovirus, estimates of protective
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between 30 and 100% [8–11]. Further, the fraction of immune indi-
viduals in the population required to stop transmission of polio-
virus depends on seasonality, geographic context, and the type of
poliovirus [12]. Thus, the number of doses that need to be deliv-
ered through a combination of routine immunization and SIAs var-
ies. While precise vaccination targets are not used, for purposes of
risk assessment countries are often considered low-risk if at least
90% of the population has three or more doses of OPV [3], in line
with the broader immunization coverage targets advocated by
the World Health Assembly [13].
For risk analysis, the GPEI relies heavily on immunization cov-
erage estimates derived from reported polio vaccination history
of non-polio acute flaccid paralysis (NP-AFP) cases [3,14]. NP-AFP
data is used for global risk assessment because it is comprehen-
sively collected and maintained by the World Health Organization
(WHO), does not rely on population estimates, and because of its
presumed comparability across geographies. However, it is widely
acknowledged that these data have several key weaknesses when
used for risk analysis, including a relatively small sample size, a
potentially non-representative sample of individuals, and incom-
plete record and recall of dose history.
Routine immunization indicators are also often used in risk
assessment, typically based on household surveys or the WHO/
United Nations Children’s Fund Estimates of National Immuniza-
tion Coverage (WUENIC) [3,14]. However, such indicators do not
measure vaccination through SIAs, and may under-estimate polio
immunity levels.1.2. Assessing vaccination history
The polio vaccination history used in risk assessment is recorded
on case investigation forms by local polio surveillance officers,
typically from a parent or caregiver of the paralyzed child. When
reporting vaccination history, the caregiver must consider vaccina-
tions from two distinct sources: routine immunization and SIAs.
Routine immunization typically occurs in a health clinic, and can
be verified through vaccination cards when available, while vacci-
nation through SIAs typically occurs at the child’s home and is
not verifiable. Thus, in ascertaining polio vaccination history, polio
surveillance officers must rely heavily on parental recall, which is
less reliable and more sensitive to the survey instrument used [15].
Case investigation forms differ by country, though global and
regional reporting requirements stipulate the minimum amount
of information that is collected [16]. In countries in the African
Region (AFR) of the WHO, the case investigation form asks for
the total number of polio vaccine doses, as well as up to 5 vaccina-
tion dates. Notably, the case investigation forms in AFR do not dis-
tinguish between doses given by SIA and by the routine program.
However, in countries in the Eastern Mediterranean Region
(EMR) and the South East Asia Region (SEAR), case investigation
forms must separately record doses received from routine
immunization and SIAs. Examples of these survey instruments
are available in the supplementary material.
In this paper, we examine how vaccination histories are influ-
enced by SIAs, how this relationship varies between countries
and regions, and how this affects risk assessment.Fig. 1. Schematic representation of exclusion criteria applied to the AFP database.2. Data and methods
Acute flaccid paralysis (AFP) cases in children under 15 years of
age are identified through the global polio surveillance network
[17]. Once a case is identified, an investigation is initiated in which
a surveillance officer collects basic clinical and demographic infor-
mation, including polio vaccination history, on a case investigationform. Two stool samples are collected within 14 days of onset and
within 24–48 h of each other and sent to a laboratory in the Global
Polio Laboratory Network for testing. Clinical information and
stool culture results are used to classify AFP cases as either polio
or non-polio AFP. Regional and global databases of AFP case data
are maintained by the WHO. From January 2010 to July 2015,
484,497 NP-AFP cases were identified in 75 countries.
The WHO also maintains a database of all supplemental polio
immunization activities. The database includes information on
the dates and location of the activity, the type of activity (National
Immunization Day, Child Health Day, etc.), the target population,
and the type of vaccine used. Campaign data from January 2000
to July 2015 were used.
We matched the campaign and AFP databases to determine the
number of vaccination campaigns occurring in each case’s district
for which the child would be eligible, prior to the onset of paralysis.
We excluded cases if they were over 59 months of age at the onset
of paralysis, had experienced more than 10 SIAs, or reported more
than 50 doses of OPV. These exclusions were applied since we do
not expect accurate vaccination histories from older children
who have experienced many SIAs, regardless of the method of
ascertainment. In the Supplementary Material we examine the
sensitivity of our analyses to this exclusion. We also restricted
our analysis to countries with 50 or more NP-AFP cases not
excluded from the above criteria, and that had conducted more
than one SIA over the time period considered. We omitted data
Table 1
Characteristics of NP-AFP Cases between January 2010 – July 2015 meeting inclusion criteria, by WHO Region.
Region Countries NP-AFP cases Age in months
(median, IQR)
% Male Under-immunized
cases (<3 OPV doses) (%)




AFR 37 40,822 18 (12,27) 55 7639 (19%) 1606 (4%) 4 (3,5) 4 (2,7)
EMR 7 16,668 16 (10,24) 57 1593 (10%) 642 (4%) 8 (5,10) 5 (3,8)
SEAR 3 72,335 17 (11,23) 58 3393 (5%) 639 (1%) 8 (6,11) 6 (3,8)
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complicate identification of campaign history. This resulted in
129,825 cases in 47 countries used in the primary analysis (see
Fig. 1). Table 1 summarizes characteristics of the children included
in the analysis, by region. Summary tables of all children by coun-
try are in the Supplementary Material.
For our primary analysis, we characterized the relationship
between caregiver-reported doses from NP-AFP cases and the
number of vaccination campaigns experienced by the case using
a linear regression model, adjusted for province to account for dif-
ferences in routine immunization coverage. This model takes the
form
Model 1 : Dosesij ¼ aAj þ bA  ð#SIAs experiencedÞ þ i;
where Dosesij are the doses reported by person i in province j, aAj is
the average number of doses reported in the absence of campaigns,
bA is the increase in average doses associated with each additional
campaign experienced, and i is a mean-zero error term. This model
estimates the increase in the expected number of doses reported on
a case investigation form for each additional vaccination campaign
experienced, averaged across provinces over the years 2010–2015.
The model is fit separately for each country. When the reported
number of doses is unbiased bA is an estimate of average campaign
coverage. However, due to imperfect ascertainment of dose histo-
ries, the estimate is more correctly interpreted as the marginalFig. 2. Total number of OPV doses reported and the number of vaccination campaigns exp
lines indicate simple linear regression fit and 95% confidence interval. Countries in top
interpretation of the references to colour in this figure legend, the reader is referred toimpact of a vaccination campaign on the average number of doses
reported on a case investigation form.
We also examined the relationship between the number of SIAs
experienced and the proportion of children reporting zero OPV
doses (the zero-dose fraction), as well as the proportion of children
reporting less than three OPV doses (also termed the under-
immunized fraction), since these are the traditional indicators used
in risk assessment. These models take the form:
Model 2 : PrðDosesij < 3Þ ¼ auj  ð1 bUÞ#SIAs experienced; andModel 3 : PrðDosesij ¼ 0Þ ¼ azj  ð1 bZÞ#SIAs experienced:
Here, auj and azj are the under-immunized and zero-dose fractions,
respectively, in the absence of vaccination campaigns. Likewise, bZ
and bu are the proportional decrease in zero-dose fraction and
under-immunized fraction, respectively, associated with each addi-
tional SIA. Models 2 and 3 are fit using modified Poisson regression
for binary data [18]. In Models 2 and 3 we omitted countries with
10 or fewer under-immunized or zero-dose cases.
Our primary interest was in characterizing the plausible impact
of SIAs on reported doses, using point-estimates and 95%
confidence intervals. We also note where confidence intervals
include 0, corresponding to a 2-sided hypothesis test of
H0 : b ¼ 0 and a Type 1 Error rate of 0:05 per-test. In all analyses,erienced by a child, based on NP-AFP data between January 2010 and July 2015. Red
panel are in the AFR, while countries in the bottom row are in EMR and SEAR. (For
the web version of this article.)
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ence on trends even when the model is not correct [19,20].3. Results
3.1. Relationship between reported doses and vaccination campaigns
experienced
Fig. 2 shows the number of SIAs experienced and the total num-
ber of OPV doses reported for children aged 6–59 months in 10
countries representing those that are endemic or recently endemic
(Pakistan, India, and Nigeria), with recent outbreaks (Cameroon
and Somalia), with high routine immunization (Ghana, Egypt,
and Bangladesh), and with low routine immunization (DRC, and
Cote D’Ivoire). The top row shows data from countries in the
AFR, while the bottom row shows data from countries in the
EMR and SEAR. Here, the strength of this relationship varies, but
appears generally stronger in those countries in the EMR and SEAR,
compared to those in the AFR. Similar figures for all 47 countries
are given in the supplementary material.
Fig. 3 summarizes the association between reported doses and
SIAs experienced using 3 different models along with 95% confi-
dence intervals for each country analyzed.Fig. 3. Estimated association between reported number of doses and number of SIAs ex
right, estimates are from models 1, 2, and 3 detailed in Section 2. Note some countries ar
insufficient cases.When examining the effect of SIAs on the average number of
doses reported, we find that 13 of the 47 countries are compatible
with the hypothesis that SIAs have no effect on the average num-
ber of doses reported. Further, in 30 of the 47 countries we esti-
mate that less than 1 in 4 SIAs experienced will result in a
reported dose of vaccine on the case investigation form (i.e. we find
the point estimate is less than 0.25). The two remaining countries
with wild poliovirus circulation in the EMR, Afghanistan and Pak-
istan, are among the countries with the strongest response to vac-
cination campaigns, with 0.55 and 0.65 additional doses reported
for each additional campaign, respectively. Nigeria’s estimated
response to campaigns is 0.30, which while lower than Afghanistan
and Pakistan is higher than the AFR aggregate estimate of 0.15
(Table 2).
We also examined the effect of SIAs on the proportion of chil-
dren reporting less than 3 doses of OPV (Model 2). This model
quantifies the proportion reduction in under-immunized fraction
associated with an additional SIA. Again, we find weak associations
between reported doses and SIAs, with no discernable effect on the
under-immunized fraction in 19 of the 41 countries with sufficient
data.
Lastly, we also examined the effect of SIAs on the proportion of
children who report zero doses of OPV (Model 3). Here, we find
similarly weak associations. In 14 of 26 countries with sufficientperienced, based on NP-AFP data between January 2010 and July 2015. From left to
e excluded from analysis of under-immunized or zero-dose fraction analyses due to
Table 2
Summary of association between reported doses and campaigns, based on NP-AFP data between January 2010 and July 2015, by WHO region.
Region NP-AFP cases Under-immunized cases Zero-dose cases SIA effect on Average
Dose (Model 1)
SIA effect on Under-
Immunized Fraction
(Model 2)
SIA effect on Zero-Dose
Fraction (Model 3)
Estimate 95% CI Estimate 95% CI Estimate 95% CI
AFR 41,179 7790 1650 0.15 (0.13, 0.17) 0.13 (0.10, 0.16) 0.09 (0.02, 0.15)
EMR 16,904 1620 644 0.45 (0.43, 0.47) 0.21 (0.19, 0.22) 0.20 (0.16, 0.23)
SEAR 73,262 3444 647 0.65 (0.62, 0.68) 0.44 (0.33, 0.53) 0.78 (0.65, 0.86)
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fraction. In 21 countries, we found that less than 1 in 4 children
who report zero doses would report one or more doses after expe-
riencing a campaign. Bangladesh showed the strongest relation-
ship between campaigns and SIAs, where, almost without
exception, zero-dose children had not experienced any SIAs.
We estimated the average SIA effect across all countries ana-
lyzed within each region, using a simple average of the indepen-
dent country-level estimates. This analysis is summarized in
Table 2. Across all three models, we find that the relationship
between SIAs and reported doses is significantly stronger in SEAR
than in EMR, and stronger in EMR than in AFR. One explanation
for the dramatically attenuated association in AFR is lower cam-
paign coverage. However, monitoring data suggests that polio
campaigns vaccinate the vast majority of eligible children in a
given area [21]. Therefore, a more plausible explanation is a major
difference in the accuracy of reported doses.
3.2. Characteristics of vaccination history on case investigation forms
While we do not know how the various survey instruments are
implemented by individual surveillance officers, additional
information from the case investigation forms give some clues
regarding how information is ascertained from a child.Fig. 4. Age of children at last recorded OPV dose (top panel), and last recorded SIA tha
January 2010 and July 2015.We examined the age at which the most recent OPV dose was
received, which is recorded in all regions, though with varying
levels of missing data (it is recorded in 31%, 74%, and 67% of AFP
cases in AFR, EMR, and SEAR, respectively). We compared this to
the child’s age at the last scheduled SIA, and summarized the
results in Fig. 4. There, we see that vaccination dates recorded on
case-investigation forms in AFR are clustered in the first year of life
when routine vaccination is given, whereas in other regions the
last vaccination recorded typically comes at an older age. We also
found that the median number of SIAs occurring in a child’s district
between the last reported OPV dose and date of onset are 4 in AFR,
compared with 0 in EMR and SEAR.
This suggests that dates recorded on case investigation forms in
AFR often correspond to routine immunization. In contrast, the
case investigation forms in EMR and SEAR, which explicitly distin-
guish between doses delivered through SIAs and routine immu-
nization, report vaccination dates and doses that are more
compatible with the number and timing of SIAs.
In order to investigate this possibility further, we compared the
proportion of children reporting 3 or more doses in NP-AFP data, to
WUENIC estimates of routine immunization coverage, by birth
cohort. Fig. 5 displays this analysis for the 10 countries displayed
in Fig. 2, while the remainder of the countries are in the supple-
mental material. In a number of countries, particularly in AFR,t occurred in their district (bottom panel), from NP-AFP cases with onset between
Fig. 5. Comparison of fully-immunized fraction from NP-AFP and WUENIC data, by birth cohort. Numbers at bottom of graph indicate median number of SIAs experienced by
NP-AFP cases used in the estimate.
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comparable to or lower than routine immunization coverage,
despite many SIAs. Unlike WUENIC estimates, NP-AFP cases are
not meant to be representative of the population. Nonetheless,
the comparison suggests that doses reported by NP-AFP cases
may under-estimate polio immunization levels in some countries.
This is most concerning in large countries with low routine immu-
nization levels, such as the DRC, in which SIAs are both epidemio-
logically critical and also expensive.
4. Discussion and conclusion
In this paper, we examined the relationship between SIAs and
the number of caregiver-reported polio vaccine doses, which are
used to assess polio immunity, risk of spread, and plan vaccination
activities. We found that in many countries this association is
startlingly weak. One would expect some attenuation of the asso-
ciation due to varying campaign coverage or imperfect recall of
vaccination history, but the lack of a discernable relationship
between polio vaccine doses and polio vaccination campaigns in
many cases prompts some concern about data quality and the
proper use of this data in risk assessment.
In current risk models, countries with poor routine immuniza-
tion coverage and a history of polio importation are often assigned
appropriately high risk using available indicators. However, our
results show that the level of risk, and the progress made towards
reducing that risk through SIAs, is distorted through poor data
quality.
Where the association between polio immunization activities
childhood immunity indicators is weak, the data suggests that
preferential recording of vaccination from routine immunization
and under-reporting of vaccinations from SIAs may play a role.
To support this claim, we found that in the EMR and SEAR regions
of the WHO, where vaccination history is collected through a more
extensive questionnaire, reported doses and vaccination cam-
paigns were generally more compatible. Modification of case
investigation forms to include more detailed vaccination history
has been recommended recently by WHO, which may improve
data quality.
Alternative risk assessments and SIA planning processes could
be based on supplementing weak routine immunization systems,
measured through vaccination records and household surveys,
which may be more accurately measured. Further, periodic study
of at-risk countries should be done, and the GPEI should considerdevoting additional resources for rigorous surveys to improve
knowledge of population immunity and SIA effectiveness. Lastly,
when planning activities based on any indicator, such as reported
vaccine doses, one should validate the indicator by examining its
historical relationship to those activities.
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